Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_3
1
33%
Ph not_applicable
2
67%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Other(3)

Detailed Status

unknown3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 31 (33.3%)
N/A2 (66.7%)

Trials by Status

unknown3100%

Recent Activity

0 active trials
Showing 3 of 3
unknownnot_applicable

Sivelestat for Acute Respiratory Distress Syndrome Due to COVID-19

NCT05697016
unknownphase_3

A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC

NCT03668496
unknownnot_applicable

An fMRI Study of Jianpi Yishen Huatan Granules for Cognitive Impairment After Acute Cerebral Infarction

NCT02752867

Clinical Trials (3)

Showing 3 of 3 trials
NCT05697016Not Applicable

Sivelestat for Acute Respiratory Distress Syndrome Due to COVID-19

Unknown
NCT03668496Phase 3

A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC

Unknown
NCT02752867Not Applicable

An fMRI Study of Jianpi Yishen Huatan Granules for Cognitive Impairment After Acute Cerebral Infarction

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3